5326492025-10-012025-12-315326492025-04-012025-12-315326492025-10-012025-12-31in-capmkt:OtherExpenses1Member5326492025-04-012025-12-31in-capmkt:OtherExpenses1Memberiso4217:INRiso4217:INRxbrli:shares532649NECLIFENOTLISTEDINE023H01027NECTAR LIFESCIENCES LIMITEDMain BoardEquity2025-04-012026-03-312026-01-232026-01-19INRLakhsQuarterlyThird quarterSingle segmentPharmaceutical Business Segment2026-01-2315:00:002026-01-2316:30:00Not applicable2025-10-012025-12-31UnauditedConsolidated066080006608000000609500030224600061900013152000322112000-3155040008815130005660090000-110249000-1102490000676258000-965726000-432165000-5335610000142697000014269700022426100013.023.02-2.38-2.380.640.641. The above financial results were reviewed by Audit Committee on January 23, 2026 and approved by the Board of Directors (“Board”) of Nectar Lifesciences Limited (“Company”) in its meeting held on January 23, 2026. The statutory auditors of the Company have conducted a “Limited Review” of the above standalone and consolidated unaudited financial results for the quarter and Nine Months ended on December 31, 2025. <BR> <BR> 2. The company is exclusively in the pharmaceutical business segment. <BR> <BR> 3. Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period. <BR> <BR> 4. The Company has one wholly owned subsidiary, namely NECLIFE PT, UNIPESSOAL LDA, which is Inoperative during the period ended on December 31, 2025. <BR> <BR> 5. Discontinued Operations <BR> A.Pharma Business <BR> <BR> On July 7, 2025, the Company entered into a Business Transfer Agreement (Pharma BTA) for the transfer of its Active Pharmaceutical Ingredients business (located at Unit 1 and Unit 2, Derabassi, Punjab) and Formulation business (located at Unit 6, Baddi, Himachal Pradesh) (Pharma Businesses) to Ceph Lifesciences Private Limited (Ceph) by way of a slump sale on a going concern basis for a total consideration of INR 127,000.00 lakhs. <BR> <BR> The transfer of the Pharma Businesses was approved by the shareholders of the Company on August 4, 2025. The slump sale was completed on November 10, 2025. Accordingly, after working capital adjustments as per the Pharma BTA, the final consolidated consideration for Pharma BTA has been determined at INR 125,398.55 lakhs. <BR> <BR> Out of the above amount, the Company has received INR 106,598.55 lakhs up to December 31, 2025, and the balance of INR 18,800.00 lakhs is receivable as at the quarter end. A resultant profit of INR 8,815.13 lakhs (net of current and deferred tax impact of INR 7,522.19 lakhs) arising from the sale of the Pharma Businesses has been recognised under Exceptional Items. <BR> <BR> B. Menthol Assets <BR> <BR> Further, the Company entered into an Asset Purchase Agreement (APA) dated July 7, 2025, for the transfer of assets relating to its menthol business (Menthol Assets) to CEPH for a consideration of INR 2,000.00 lakhs. The Menthol Asset transfer was completed on November 10, 2025. The Company has received the full consideration under the APA up to December 31, 2025. <BR> <BR> C. Capsule Business (EHGC) <BR> <BR> Further, on December 20, 2025, the Company entered into a Business Transfer Agreement (Capsule BTA) with Capnest Health Care Private Limited (Capnest) for Sale of its business of manufacture, distribution and marketing of Empty Hard Gelatin Capsule (located at Village Bhatoli Kalan, Pargana Dharmpur, Tehsil Baddi, District Solan, Himachal Pradesh) (Capsule Business) of the Company. <BR> <BR> The transaction is for a consideration of INR 1,990.00 lakhs along with the takeover of accounts receivable and payables/ creditors by the Capnest, or such other working capital adjustments as specified in the Capsule BTA. <BR> <BR> The sale is structured as a slump sale on a going concern basis and is subject to approval from the Government of Himachal Pradesh under Section 118 of the Himachal Pradesh Tenancy and Land Reforms Act, 1972. The transaction shall be completed in accordance with the terms set out in the Capsule BTA.\ <BR> <BR> Further, in the unaudited standalone financial results, the net results of Pharma Businesses, Menthol Assets and Capsule Business has been disclosed separately as discontinued operation as required by Indian Accounting Standard (Ind AS) 105 – Asset Held for Sale and Discontinued Operations and Schedule III to the Companies Act, 2013. Consequently, the Company's Statement of Profit and Loss for the period ended December 31, 2025 pertains to its continuing operations only and for that purpose the results for the other reporting periods i.e., 30-Sep-25, 31-Dec-24 and 31-Mar-25, have been restated accordingly. <BR> <BR> Operations relating to the Pharma Business, Assets and Capsule Business in respect of total income, total expenses and tax are being disclosed separately as Discontinued operations as part of the results below: <BR> <BR> INR in lakhs <BR> <BR> S. No. Particulars Quarter Ended 9 Months Ended Year Ended <BR> 31-Dec-25 30-Sep-25 31-Dec-24 31-Dec-25 31-Dec-24 31-Mar-25 <BR> Restated Restated Restated Restated Restated <BR> Unaudited Unaudited Unaudited Unaudited Unaudited Audited <BR> 1 Revenue from operations 2,173.55 9,327.02 45,433.44 39,567.08 1,24,106.60 1,66,997.36 <BR> 2 Other income 1,214.40 2.56 74.98 1,221.64 143.24 336.06 <BR> 3 Total expenses 13,045.21 36,428.28 44,288.84 87,233.65 1,21,760.27 1,83,581.54 <BR> 4 Profit before tax (9,657.26) (27,098.70) 1,219.58 (46,444.93) 2,489.57 (16,248.12) <BR> 5 Tax expenses (4,321.65) (9,467.90) 458.44 (17,146.63) 929.09 (4,818.42) <BR> 6 Net profit after tax (5,335.61) (17,630.80) 761.14 (29,298.30) 1,560.48 (11,429.70) <BR> <BR> 6.Buy-back of Equity Shares <BR> <BR> The Board, at its meeting held on December 03, 2025, approved a proposal for the Company to buy back its fully paid-up equity shares (face value of INR 1/- each) at a price of INR 27.00 per share for an aggregate amount of INR 8,100.00 lakhs. The buyback offer comprises the purchase of 3,00,00,000 equity shares, representing approximately 13.38% of the total paid-up equity share capital of the Company as at March 31, 2025. <BR> <BR> The buyback is proposed to be made from all equity shareholders of the Company, excluding the Promoters and members of the Promoter Group, as on the record date, on a proportionate basis through the “Tender Offer” route, in accordance and consonance with the provisions of the Companies Act, 2013 (Act) and the SEBI (Buy Back of Securities) Regulations, 2018 (Buyback Regulations) (including any statutory modification(s) or re-enactment thereof) and the rules made and circulars issued thereunder. <BR> <BR> The payment for the buy back has been made by the Company on January 13, 2026 and the 3,00,00,000 equity shares has been extinguished by the National Securities Depository Limited (NSDL) on January 20,2026. <BR> <BR> All the relevant dates being subsequent to the financial reporting date, no effect of the buy-back has been recognized in the Statement of Profit and Loss for the quarter ended December 31, 2025. <BR> <BR> 7. Extraordinary and Exceptional items – Refer Note 5.2025-04-012025-12-31UnauditedConsolidated017109000171090000006500000302247000259800015267000326612000-3095030008815130005720100000-108152000-1081520000680162000-4644493000-1714663000-29298300000-22496680001000-224966700022426100013.033.03-13.06-13.06-10.03-10.03Other Expenses13152000Other Expenses152670000-100001000